Lung involvement raises costs for systemic sclerosis patients

Lung involvement raises costs for systemic sclerosis patients PharmacoEconomics & Outcomes News 792, p16 - 2 Dec 2017 Lung involvement raises costs for systemic sclerosis patients Interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH) substantially increase healthcare costs and have poorer survival outcomes for patients with systemic sclerosis, according to a group of US- based researchers. The retrospective cohort analysis estimated all-cause healthcare use and costs (2014 values) from nationwide claims databases. Data were collected for patients with newly-diagnosed (incident) systemic sclerosis with or without ILD and/or PAH, who were continuously enrolled over a 5-year period. Of patients with continuous enrolment over a 5-year period, 1957 had incident systemic sclerosis, 219 had ILD-related disease and 108 had PAH-related disease. Average all-cause healthcare costs were substantially higher for patients with ILD- ($US191 107) and PAH- related disease ($254 425) over 5 years, compared with patients with non-lung-involved systemic sclerosis ($101 839). A similar pattern was seen for annual costs, where they ranged from $31 285 to $55 446 for the ILD group, $44 454 to $63 320 for the PAH group, and $18 513 to $23 268 for non-lung-involved disease. Median survival time was significantly shorter in the ILD and PAH groups (11.3, 8.8 vs 6.0 years, respectively; p < 0.001). "These data highlight that there remains an unmet need to identify more effective therapeutic strategies for both ILD and PAH", conclude the authors. * Funded by Genentech Inc and F. Hoffmann-La Roche. Fischer A, et al. All-cause Healthcare Costs and Mortality in Patients with Systemic Sclerosis with Lung Involvement. The Journal of Rheumatology : 15 Nov 2017 803284966 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png PharmacoEconomics & Outcomes News Springer Journals

Lung involvement raises costs for systemic sclerosis patients

Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/lung-involvement-raises-costs-for-systemic-sclerosis-patients-RikPnvas09
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
ISSN
1173-5503
eISSN
1179-2043
D.O.I.
10.1007/s40274-017-4539-x
Publisher site
See Article on Publisher Site

Abstract

PharmacoEconomics & Outcomes News 792, p16 - 2 Dec 2017 Lung involvement raises costs for systemic sclerosis patients Interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH) substantially increase healthcare costs and have poorer survival outcomes for patients with systemic sclerosis, according to a group of US- based researchers. The retrospective cohort analysis estimated all-cause healthcare use and costs (2014 values) from nationwide claims databases. Data were collected for patients with newly-diagnosed (incident) systemic sclerosis with or without ILD and/or PAH, who were continuously enrolled over a 5-year period. Of patients with continuous enrolment over a 5-year period, 1957 had incident systemic sclerosis, 219 had ILD-related disease and 108 had PAH-related disease. Average all-cause healthcare costs were substantially higher for patients with ILD- ($US191 107) and PAH- related disease ($254 425) over 5 years, compared with patients with non-lung-involved systemic sclerosis ($101 839). A similar pattern was seen for annual costs, where they ranged from $31 285 to $55 446 for the ILD group, $44 454 to $63 320 for the PAH group, and $18 513 to $23 268 for non-lung-involved disease. Median survival time was significantly shorter in the ILD and PAH groups (11.3, 8.8 vs 6.0 years, respectively; p < 0.001). "These data highlight that there remains an unmet need to identify more effective therapeutic strategies for both ILD and PAH", conclude the authors. * Funded by Genentech Inc and F. Hoffmann-La Roche. Fischer A, et al. All-cause Healthcare Costs and Mortality in Patients with Systemic Sclerosis with Lung Involvement. The Journal of Rheumatology : 15 Nov 2017 803284966 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792

Journal

PharmacoEconomics & Outcomes NewsSpringer Journals

Published: Dec 2, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off